Evolus (NASDAQ:EOLS) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Evolus (NASDAQ:EOLS) released its earnings results on Monday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02), FiscalAI reports. The company had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million.

Evolus Price Performance

Shares of EOLS stock traded up $0.25 during trading hours on Monday, reaching $5.58. The company had a trading volume of 2,070,149 shares, compared to its average volume of 1,165,202. Evolus has a 12 month low of $3.86 and a 12 month high of $12.24. The business has a fifty day simple moving average of $4.68 and a 200-day simple moving average of $5.63. The company has a market cap of $363.03 million, a price-to-earnings ratio of -6.89 and a beta of 1.28.

Insider Transactions at Evolus

In related news, insider Rui Avelar sold 29,996 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44. Following the transaction, the insider directly owned 430,542 shares of the company’s stock, valued at $2,105,350.38. This trade represents a 6.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Moatazedi sold 116,720 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $570,760.80. Following the transaction, the insider directly owned 618,369 shares in the company, valued at $3,023,824.41. The trade was a 15.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 163,504 shares of company stock worth $797,184 over the last three months. 6.10% of the stock is owned by insiders.

Institutional Trading of Evolus

Hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. bought a new stake in Evolus during the fourth quarter worth $34,000. Wexford Capital LP bought a new stake in Evolus during the third quarter worth $37,000. Aquatic Capital Management LLC bought a new stake in Evolus during the third quarter worth $48,000. State of Wyoming bought a new stake in Evolus during the fourth quarter worth $63,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Evolus by 340.2% during the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after acquiring an additional 5,691 shares during the period. 90.69% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Weiss Ratings cut Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, April 24th. Mizuho set a $15.00 target price on shares of Evolus in a research note on Wednesday, February 4th. Wall Street Zen lowered shares of Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. HC Wainwright cut their target price on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, Stifel Nicolaus decreased their target price on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, January 13th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.00.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.